Recent

% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • maddison3 maddison3 Nov 5, 2013 6:47 AM Flag

    ASH abstracts

    Will be released on Thursday, Nov. 7th.....Should be a price move catalyst...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Thoughts about Gern study coming out also on Thursday? read Adam Feuerstein| report on Gern today and how it might effect Incyte.?

      • 3 Replies to nimoman57
      • The remissions business is about 95% red herring. Basically, the usual experience in cancer treatment is that remissions are relatively short-term. MF is a chronic disease, so DURABLE clinical improvement is the objective [of course, remission, as long as it lasts, is a nice kind of clinical improvement]. In the nature of business, you don't want to have to show anything subtle or long-term in a registration study (too expensive to run the study). So on a reasonable time horizon, the issue for Incyte is clinical improvement. The differing adverse event profiles of the two drugs also feeds into a market analysis.

        This one isn't going to be settled by early-phase trial results (barring a flop, of course)

      • The remissions business is about 95% red herring. Basically, the usual experience in cancer treatment is that remissions are relatively short-term. MF is a chronic disease, so DURABLE clinical improvement is the objective [of course, remission, as long as it lasts, is a nice kind of clinical improvement]. In the nature of business, you don't want to have to show anything subtle or long-term in a registration study (too expensive to run the study). So on a reasonable time horizon, the issue for Incyte is clinical improvement. The differing adverse event profiles of the two drugs also feeds into a market analysis.

        This one isn't going to be settled by early-phase trial results (barring a flop, of course)

      • The remissions business is about 95% red herring. Basically, the usual experience in cancer treatment is that remissions are relatively short-term. MF is a chronic disease, so DURABLE clinical improvement is the objective [of course, remission, as long as it lasts, is a nice kind of clinical improvement]. In the nature of business, you don't want to have to show anything subtle or long-term in a registration study (too expensive to run the study). So on a reasonable time horizon, the issue for Incyte is clinical improvement. The differing adverse event profiles of the two drugs also feeds into a market analysis.

        This one isn't going to be settled by early-phase trial results (barring a flop, of course)

 
INCY
86.96+0.53(+0.61%)Jul 26 4:00 PMEDT